Matti Aapro
Board Member, All.Can International, President, European Cancer Organisation and Board Member, Clinique de Genolier
Dr Matti Aapro is a medical oncologist, Board Member of All.Can, Director of the Genolier Cancer Center in Switzerland, President of the European Cancer Organisation, President of Sharing Progress in Cancer Care, and Board Member of the European School of Oncology and the International Society for Geriatric Oncology. He is also an Editor of the Journal of Cancer Policy, Honorary Editor of Critical Reviews in Oncology/Hematology, Associate Editor for the geriatric section of The Oncologist and an Editorial Board member of the Journal of Geriatric Oncology and Annals of Oncology. His main interest areas are new drug development, breast cancer, cancer in the elderly and supportive care.
Virginia Abello
Medical doctor graduated from the Universidad del Rosario with a specialization in Internal Medicine and Hematology from the FUCS University
Medical doctor graduated from the Universidad del Rosario with a specialization in Internal Medicine and Hematology from the FUCS University. She has published more than 40 research articles in different academic journals. Parallel to her work as a hematologist, she is currently the president of the Colombian Association of Hematology and Oncology (ACHO) and she is one of the main allies of the All.Can Colombia coalition. She has been awarded the Hernando Sarastí and Dr. Luis Sánchez Medal Awards, among others.
Cary Adams
CHIEF EXECUTIVE OFFICER, UNION FOR INTERNATIONAL CANCER CONTROL (UICC)
Born in London, Dr. Cary Adams has a BSc Honours degree in Economics, Computing and Statistics from the University of Bath, United Kingdom and a Masters degree (with Distinction) in Business Administration. He is a Harvard Business School Alumni having attended the School’s Executive General Management programme in 2003. In 2009, Dr. Adams made a career change, moving from the management of international businesses in the banking sector to become CEO of UICC based in Geneva. UICC unites the cancer community to reduce the global cancer burden, to promote greater equity, and to integrate cancer control into the world health and development agenda. Its rapidly increasing membership base of over 1000 organisations in more than 160 countries features the world’s major cancer societies, ministries of health and patient groups and includes influential policy makers, researchers and experts in cancer prevention and control. UICC also boasts more than 55 strategic partners. Dr. Adams and his team focus on global advocacy, convening the cancer community (through World Cancer Day, the World Cancer Congress and the World Cancer Leaders’ Summit) and running significant global capacity building projects that address global cancer issues. Dr. Adams has also served as Chair of the NCD Alliance, a coalition of around 2,000 organisations working on non-communicable diseases, which include cancer, diabetes, heart, respiratory, mental and neurological diseases. In 2014, he was awarded an Honorary Doctorate in International Relations from the University for Business and International Studies in Geneva and in 2015, an Honorary Doctorate in Health from Bath University in the UK. In May 2015, Dr. Adams was awarded ‘CEO of the year’ at the International and European Association conference organised by the Associations Network
Tit Albreht
Health Services Research at the University of Amsterdam, Head of the Centre for Health Care at the National Institute of Public Health of Slovenia, Senior Researcher in the field of health services research, health policy and health systems research, Member of the Scientific Committee of EUPHA, President of the Slovenian Preventive Medicine Society
Dr. Tit Albreht, M.D. (1961), Slovenian, Ph.D. in Health Services Research at the University of Amsterdam, Head of the Centre for Health Care at the National Institute of Public Health of Slovenia, Senior Researcher in the field of health services research, health policy and health systems research, Member of the Scientific Committee of EUPHA, President of the Slovenian Preventive Medicine Society. He has worked on national and EU policies in cancer control and cancer care since 2006. His first task was leading the project of support to the first Slovenian Presidency to the Council of the EU between 2006 and 2008, the FACT project. From 2011 to 2014, he was a work package leader of the Work Package in the Joint Action EPAAC – European Partnership for Action Against Cancer. This process resulted in the European Guide on National Cancer Control Programmes. Between 2014 and 2017, he was the scientific co-ordinator of the Joint Action CanCon (Cancer Control), an EU co-financed project dedicated to informing the development of cancer policies at the EU and Member State levels. Currently, he is the scientific coordinator of the Joint Action innovative Partnership for Action Against Cancer (JA iPAAC), which came to the close at the end of December 2021. He is an Assistant Professor of Public Health at the Medical Faculty of Ljubljana, Slovenia as well as at the Faculties of Medicine and Health Sciences of the University of Maribor, where he is leading on public health and epidemiology and health promotion. He is the main, lead or key author of 40 publications listed in PubMed. He acts as a reviewer of several scientific journals and of projects submitted for financing to the European Commission.
Ksenia Crane
Research Fellow at the University of Southampton's School of Healthcare Enterprise and Innovation
Dr Ksenia Crane is a Research Fellow at the University of Southampton's School of Healthcare Enterprise and Innovation. Her expertise is in multidisciplinary qualitative research, including health research and meta-research, which she delivers as part of the School's permanent government contract with the National Institutes of Health and Care Research (NIHR) and as part of other high-profile contracts with organisations such as the Health Value Alliance (HVA). Dr Crane's recent research (delivered with the NIHR's Insight team) has focused on peer review and decision-making, post-award management of funded research, researcher burden, and health research design & methodology. She was also lead on an academic report on metrics in cancer care for HVA. Prior to this, she has worked as a scientific/journal editor and held the position of Senior Research Fellow in Neurodegeneration, based at the University's Biological Sciences and the University Hospital Southampton. Her previous research achievements are in the field of Alzheimer's research, and she holds a PhD in Neuroscience and a BSc in Pharmacology.
Guillaume Dedet
Senior health economist at the OECD Health Division
Guillaume Dedet currently serves as senior health economist at the OECD Health Division. He is responsible of a project on inequalities in cancer care and prevention in the EU, as well as OECD/EU’s regular cycles of comparative analysis of health systems and populations' health across Europe (State of Health in the EU). Dedet is a lecturer at SciencesPo Paris and is the current Secretary of the French Public Health Association (SFSP). Priori joining the OECD, he worked as medical adviser at the French Ministry of Health (Health Systems Financing Department) and as technical officer at the WHO Regional Office for Europe (Division of Health Systems and Public Health). Dedet holds a MBBS from the University of Montpellier, France, a MD in Public Health from the Greater Paris Academic Hospital and three additional post-graduate degrees (M.Sc. in statistics from University Paris-Sud, M.Sc. and Health Policy Planning and Financing from LSE and M.A. in Global Diplomacy from SOAS).
Amadou Diarra
Senior Vice President Global Policy & Government Affairs, BMS
Amadou joined Bristol Myers Squibb (BMS) in 1991. He is currently the Senior Vice President for Global Policy & Government Affairs and he represents BMS as an American Associate of the Science & Technology in Society Forum, a Member of the Pharmaceutical Research and Manufacturers of America International Section Executive Committee, and Council Chair of the International Federation of Pharmaceutical Manufacturers & Associations, where he also chairs the Value & Access Committee. At BMS, Amadou is a member of the Global Leadership Team as well as the Global Diversity & Inclusion Council and Sustainability Council. Amadou holds a Doctorate in Pharmacy from University of Tours and an MBA from École Supérieure de Commerce de Tours, and he has completed the INSEAD General Management Program.
Alex Filicevas
President, All.Can International and Executive Director, World Bladder Cancer Patient Coalition
Alex Filicevas serves as the President of the All.Can International. He was part of All.Can since its first year, also serving as a Steering Committee member since 2018. Alex is also the Executive Director of the World Bladder Cancer Patient Coalition (WBCPC), where he leads the work of the organisation to foster an international community of strong bladder cancer patient advocates. Alex is an EUPATI graduate and prior to joining the World Bladder Cancer Patient Coalition, he was leading EU affairs work at Europe’s largest cancer patient umbrella organisation, where he focused on advocacy activities, capacity building and policy initiatives with a particular focus on overarching issues faced by cancer patients and their carers in Europe. As a consultant, Alex has supported a number of private and non- governmental organisations in successful advocacy efforts at the EU level on a range of disease areas and issue-specific public health challenges.
Giovanni Gorgoni
CEO of AReSS Puglia, Chairman of EUREGHA (European Regional and Local Health Authorities), treasurer of EuroHealthNet (health promotion and health inequalities) and member of the executive board of EHTEL (eHealth and telemedicine), vice president of italian network NISAN (health clinical costing) and professor of Public Management at Bari LUM University
Giovanni Gorgoni, born in 1971, is an economist with university degree in Business Economics at Milan Bocconi University, master degree in Healthcare Management at Milan Bocconi School of Management and master degree in Facility Management at Rome Campus Bio-Medico University. He’s always been working in healthcare sector with different roles: advisor, private and public manager, professor. His professional interests are public health, health communication, healthcare management, network and pathway designing, e-Health and care intelligence. From December 2016 up till now is Chief Executive Officer of AreSS Puglia (Agenzia Regionale Strategica per la Salute e il Sociale Puglia), the Apulia government agency for strategic planning in health and social policies and for exploration in healthcare processes and technology. During current appointment he designed and developed seven regional clinical networks (cancer, rare disease, reumatology, hematology, stroke, heart and trauma), implemented eight value-based labs for Apulian Health System (clinical networks design, health pathways design, lean healthcare, health clinical costing, outcomes measurement, service humanization, communication for health and integrated care) and established the first regional center for telemedicine. From October 2015 to November 2016 he was Head of Department for Health Promotion, Social Welfare and Sport for All - Apulia Region, accountable for administration of health and social policies for Apulia Region with organizational connection to regional government and annual budget of early € 7,2 billions. The main result of this appointment was the whole re-engineering of regional hospital network - 13.000 beds and 60 centers. From January 2015 to October 2015 he was CEO of Lecce Local Health Authority in Apulia (7.900 employees, 6 hospitals, 148 community care sites and 803.000 citizens). From July 2011 to December 2014 he was CEO of BAT Local Health Authority in Apulia (3.600 employees, 5 hospitals, 48 community care sites and 390.000 citizens). Before July 2011 he served in Lazio Health System as CFO and COO at Viterbo Local Health Authority (2000-2008) and as Chief Facility Officer at Rome/E Local Health Authority (2008-2011). Previously - in Milan - he worked as operations manager in Humanitas Clinical Institute and as healthcare consultant in KPMG Advisory. Currently he’s also chairman of EUREGHA (European Regional and Local Health Authorities, treasurer of EuroHealthNet (health promotion and health inequalities) and member of the executive board of EHTEL (eHealth and telemedicine), vice president of italian network NISAN (health clinical costing), member of Executive Board of National Program for Chronic Diseases and professor of Public Management at Bari LUM University. From February 2018 he’s included in national register of eligible Healthcare CEOs.
Nigel Hughes
Project Lead for the IMI2 European Health Data & Evidence Network (EHDEN)
Nigel Hughes has a thirty-five year career spanning the NHS in the UK (16 years), NGOs and patient organisations (10 years) and within the pharmaceutical industry (17 years). He has worked clinically in HIV and viral hepatitis, liver disease, and in sales & marketing, medical affairs, market access and health economics, R&D, precision medicine, advanced diagnostics, health IT and Real World Data/Real World Medicine. His experience covers clinical, education, as an advisor, consulting, communications and lobbying over the years. He is currently the Project Lead for the IMI2 European Health Data & Evidence Network (EHDEN), and was Platform Co-Lead for the IMI1 European Medical Information Framework (EMIF), as well as consulting on numerous projects and programmes in the domain of RWD/RWE.
Rafal Matkowski
Head of Division of Surgical Oncology and of Department of Oncology of Wrocław Medical University
Head of Division of Surgical Oncology and of Department of Oncology of Wrocław Medical University and Clinical Director of Breast Unit in Lower Silesian Oncology, Pulmonology and Hematology Center (DCOPIH) and Head of Department of Breast Surgery He has been appointed to co-create the Polish Cancer Plan and the National Program for Combating Cancer and a member of the State Examination Board in the field of oncological surgery. He is also an author and coauthor of numerous scientific publications.
Dr. Hadi Mohamad Abu Rasheed
Scientific Advisor and the Head of the Professional Development and Scientific Research Department and the Qatar Cancer Society (QCS)
Dr. Hadi is the Scientific Advisor and the Head of the Professional Development and Scientific Research Department and the Qatar Cancer Society (QCS). Dr. Hadi is the representative member of the QCS in the National Cancer Governance Board in Qatar, the Gulf Federation for Cancer Control, the Union International for Cancer Control, the World Cancer Day Advisory Group, the World Ovarian Cancer Coalition, and the All.Can International. Dr. Hadi is a preceptor at the Department of Public Health - College of Health Sciences - Qatar University, Psychology and Social Work Master's Program at the Doha Institute for Graduate Studies, The University of Doha for Science and Technology’s School of Health Sciences, and Hamad Medical Corporation community medicine residency program. Dr. Hadi graduated from the University of Aleppo – Faculty of Medicine in Syria and completed his post-graduate training at the University of Iowa in the USA. Dr. Hadi presented at more than 100 medical conferences and was involved as a Co-PI in research projects that have earnt grants of around half a million dollars in the USA and Qatar. Dr. Hadi's research interests are pediatric diseases, cancer burden, cancer education and awareness, continuing medical education, Knowledge Attitudes Perception studies related to cancer, quality of life of people living with cancer, health literacy, cancer survival studies, equity in cancer care, narrative medicine and cancer, palliative care, the role of civil societies in cancer control, social media and cancer awareness, and efficiency and efficacy in cancer control and public health.
Alejandro Mohar Betancourt
Head of the Coordinating Commission of the National Institutes of Health and High Specialty Hospitals
Dr. Alejandro Mohar Betancourt. He was Head of the Coordinating Commission of the National Institutes of Health and High Specialty Hospitals (December 1, 2018 to September 30, 2019); Member of the Governing Board of the International Union Against Cancer UICC (2017-2020). Researcher in Medical Sciences "F" at the National Cancer Institute (2013-2022). Deputy General Director of Cancer Prevention and Control Programs of the Ministry of Health (2017-2018). Member of the Governing Board of the National Autonomous University of Mexico (UNAM)) 2008-2017; and Member of the International Narcotics Control Board (INCB) of the United Nations Vienna, 2013-2016. General Director of the National Institute of Cancerology from 2003 to 2013. Under his leadership, the institution became a leader in cancer research, teaching and medical care in Mexico. To date Executive Officer of the South Western Oncology Group (SWOG) for International Affairs; National Researcher Level III of the National System of Researchers of the National Council of Science and Technology (CONACYT); Senior Researcher "C" of the Department of Genomic Medicine and Environmental Toxicology of the Institute of Biomedical Research of the UNAM; Investigator of the Cancer Therapy Evaluation Program of the Division of Cancer Treatment and Diagnosis of the National Cancer Institute; Coordinator of the Unit for Biomedical Cancer Research at the National Cancer Institute & Biomedical Research Institute of UNAM. Medical Surgeon from the National Autonomous University of Mexico (UNAM.1981), specialist in Pathological Anatomy from the same university and the National Institute of Medical Sciences and Nutrition (1985). He completed a Master's and Doctorate in Epidemiology at the Harvard University School of Public Health, in the United States (1990). In 2020, he was appointed the Edward Laroque Tinker Visiting Professor, Stanford University. He is a member of the Thesis Committee of the Doctoral Program in Medical Sciences of the Faculty of Medicine, both at UNAM. In April 2012, he received the Miguel Otero Award for Clinical Research awarded by the General Health Council; In March 2017 he received the “Dr. Miguel E. Bustamante” by the National Institute of Public Health. In May 2017, he received the “Dr. Guillermo Soberón Acevedo “Development of Institutions” by the General Health Council. He belongs to several national and international scientific associations, including: The Mexican Council of Pathological Anatomy, the National Academy of Medicine, the Mexican Academy of Sciences, the Harvard Alumnae Association, the American Society of Clinical Oncology, and the South Western Oncology Group. He has 260 national and international publications, 525 works and participations in national and foreign congresses, six books and 35 book chapters, and 10,154 citations to his published works. He has received multiple awards and distinctions from government and academic entities, for his contribution to research and the training of human resources in cancer.
Matthew Hickey
Senior radiotherapist, Founder of The Health Value Alliance
Head of Division of Surgical Oncology and of Department of Oncology of Wrocław Medical University and Clinical Director of Breast Unit in Lower Silesian Oncology, Pulmonology and Hematology Center (DCOPIH) and Head of Department of Breast Surgery He has been appointed to co-create the Polish Cancer Plan and the National Program for Combating Cancer and a member of the State Examination Board in the field of oncological surgery. He is also an author and coauthor of numerous scientific publications.
Kay Lakin
Evaluation and Impact specialist within the School of Healthcare, Enterprise and Innovation (HEI)
Kay joined the University of Southampton in 2016 as an Evaluation and Impact specialist within the School of Healthcare, Enterprise and Innovation (HEI). Kay brings experience in Monitoring, Evaluation and Learning (MEL) approaches as well as mixed methods impact assessment and evaluation working with third and public sector organisations. Kay’s current areas of work include a scoping review of Academic Research Culture; collaborating with Marie Curie (UK) to map and analyse National Institute for Health and Social care Research’s (NIHR) and Marie Curie’s investment in palliative and end of life care, and over the last 12 months, she has led on the development and assessment of a package of partnership outcome indicators as part of the NIHR Outcomes Framework. Before joining the HEI, Kay worked in the third sector as a Monitoring and Evaluation lead on a number of large multi-stakeholder government funded programmes.
Gavin Lewis
Vice President, Global Value and Access, Amgen (Europe) GmbH Rotkreuz, Switzerland
Gavin Lewis is Amgen’s VP and Global Head of Value and Access, based in Switzerland. Amgen is a global leader in biotechnology. A post-graduate Health Economist from York University, Gavin originally worked in the public sector as an economist for the Scottish Government Health Department before joining the pharmaceutical industry where he has over 20 years’ experience in the field of HTA, pricing and market access. During this time Gavin has held various leadership positions at country, regional and global levels, also working at Roche and AstraZeneca.
Lydia Makaroff
President of the World Bladder Cancer Patient Coalition and CEO of Fight Bladder Cancer in the UK
Dr Lydia Makaroff is the President of the World Bladder Cancer Patient Coalition and CEO of Fight Bladder Cancer in the UK. Prior to her current roles, she was the Director of Europe’s largest cancer patient umbrella organisation. Lydia holds a PhD in immunology and a Masters' degree in Public Health and has over ten years of international work experience in non-communicable disease research and policy. She has worked across many different sectors in health: in academia, the pharmaceutical industry, and the non-profit sector. She previously conducted medical research at the Australian National University; worked as a senior post-doctoral fellow at the University of Washington; and for the International Diabetes Federation.
Vivek Muthu
Managing Director, Marivek Healthcare Consulting
Dr Vivek Muthu’s work focuses on health systems sustainability, value and efficiency. Starting at the British Medical Journal, he helped to develop and lead a team examining the clinical value of drugs and devices. He then founded Bazian, a company providing analytics and evidence to payers and providers, to help them deliver high-quality, safe, cost effective care. Bazian was acquired by the Economist Group to create its healthcare practice, which was led by Vivek. Vivek now holds non-executive and advisory positions in a number of healthcare companies and is involved in health policy initiatives focused on improving equity, sustainability and efficiency on health systems. He regularly chairs, and speaks at, international summits on these topics for the Economist, for industry, and for NGO and third sector participants in healthcare.
Ana Paula
Psycho-oncology and Palliative Care from the University Miguel de Cervantes
Ana Paula León is a Surgeon with a master's degree in Psycho-oncology and Palliative Care from the University Miguel de Cervantes, Spain. She has participated in the coordination and management of training programs for health professionals, patients and caregivers in matters of advocacy, health literacy, patient experience and strategies of health communication. She has been a leader in the coordination of health projects directed to patients and relatives affected by a chronic or complex disease. Ana Paula has participated in academic activities, round tables, medical presentations, forums and scientific manifestos on the approach of patient center care. She is the Deputy Director of "Universidad del paciente y la familia", an organization member of the Steering Committee of All.Can Argentina.
Cindy Perettie
Head of Molecular Lab Solutions based in Pleasanton
Cindy Perettie is the Head of Molecular Lab Solutions based in Pleasanton, California on April 6, 2021. Prior to that she was at Foundation Medicine starting in February 2019 as its Chief Executive Officer. Ms. Perettie is passionate about improving the care of cancer patients and brings more than two decades of scientific and commercial experience with global biopharmaceutical organizations. Prior to joining Foundation Medicine, Ms. Perettie served as senior vice president in global oncology product strategy for Roche’s Oncology unit, where she led one of the largest global oncology portfolios in the industry. Ms. Perettie began her tenure at Genentech as a program team leader for Avastin, and she led several successful therapy launches in the U.S. and abroad for Roche and Genentech across the oncology portfolio.. Since joining in 2004, she held roles of increasing responsibility at Genentech, including vice president of global regulatory operations and regional head of Europe, Middle East and Africa operations and global development. In 2012, Ms. Perettie took a hiatus from Genentech to join Sarah Cannon Research Institute (SCRI) as President, Global Development Innovations where she gained invaluable insights into the day-to-day care of people living with cancer. During her tenure, she was responsible for leading and growing SCRI’s contract research organization globally, driving critical oncology clinical trials to further expand options for cancer patients and access precision medicine. Before joining Genentech, Ms. Perettie lead portfolio management at IVAX Pharmaceuticals and was the director of global program management at Élan Corporation. Her pharmaceutical experience began as a research scientist associate director role at Chiron Corporation. She started her career as a senior research associate at Johns Hopkins University.
Bill Petch
Co-Chair of All.Can Australia’s expert Steering Committee & Former CEO of the Leukaemia Foundation of Australia
Bill Petch is the Co-Chair of All.Can Australia’s expert Steering Committee and a former CEO of the Leukaemia Foundation of Australia. He was responsible for the merger of the Leukaemia Foundation that has seen it become one of the leading patient organisations representing and supporting all blood cancer patients in Australia. Bill’s interests and contributions also span beyond blood cancers, including innovating in other health areas such as respiratory disease, eye diseases and patient journey. Bill is currently supporting the scaling of startups using virtual reality to help patients be more informed during their journey and new tech solutions to help diagnose eye conditions in remote and disadvantaged communities Bill conducted one the largest and most comprehensive surveys of blood cancer patients that identified over 700 unmet needs all linked to issues relating to access; be it information, treatment or support. This led to the development of the Zero lives lost to blood cancer by 2035 strategy and to the release of the very first ‘State of the Nation’ report on blood cancer in Australia. He also established the inaugural national taskforce into blood cancer that brought together experts from around the country and delivered the first national action plan for blood cancer to the federal health minister. Bill joined All.Can Australia to leverage his experience and drive better patient outcomes, as well as provide viable solutions to improve efficiencies in cancer care. Aligned with All.Can’s mission, Bill is focused on working with the Steering Committee to create a more patient centric health system that drives better outcomes for all cancer patients.
Eduardo Pisani
All.Can International
Eduardo Pisani has contributed to advancing public policy discussions from a close vantage point, having over three decades of international experience in senior roles for global healthcare companies and associations. He spent most of his professional life in Brussels and Geneva, where he gained an in-depth knowledge of the functioning of the European Union and of multilateral organisations, particularly in the area of health and pharmaceutical policy and legislation. For over 7 years, he led the dialogue between research-based pharmaceutical companies and associations with the United Nations and its specialised agencies, other international organisations and national government representations. He served on the board of international and European groups and on various advisory boards. He is currently leading All.Can International, and is active in a digital health start-up venture with a social impact mission focused on low-and middle-income countries in Africa and Asia. Eduardo has a degree in Law from the University of Catania, Italy.
Walter Ricciardi
MD, MPH, MSc, Hon PhD
Professor of Hygiene and Public Health at Università Cattolica del Sacro Cuore, Rome. Scientific Advisor to the Italian Minister of Health for the coronavirus pandemia. Scientific Director of Istituti Clinici Scientifici Maugeri. President of the World Federation of Public Health Associations (WFPHA). President of Mission Board for Cancer of European Commission. Coordinator of the Scientific Advisory Board of Human Technopole Foundation. Member of the Scientific Advisory Board of the Pan-European Commission on Health and Sustainable Development: Rethinking policy priorities in the light of pandemics-World Health Organization –Regional Office for Europe. Member of the Scientific Board, Santé Publique France. Ordinary Member of Pontificia Academia pro Vita, Vatican. Principal Investigator of EC Grant “TO REACH” the first health services and health systems research programme funded by European Commission(since 2016).Italian Representative in the Executive Board of World Health Organisation (November 2017-May 2020). Head of Department of Woman and Child Health and Public Health of Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Università Cattolica del Sacro Cuore (from January to December 2019). Former President of Istituto Superiore di Sanità (Italian National Institute of Health)(2015-2018) and its Commissioner from July 2014 to July 2015. Member of the Expert Panel on effective ways of investing in Health(European Commission, DG –SANTE) for two three-year mandates (2013-2019). Executive Board Member of the National Board of Medical Examiners of the United States of America (NBME) (2009-2015).President of European Public Health Association (EUPHA) (2010-2014); since 2014 he is Past President of EUPHA. Member of the III Sezione del Consiglio Superiore di Sanità, Ministry of Health (December 2009 –July 2010) and its President (December 2010 –July 2014). Founder and Director of Osservatorio Nazionale per la salute delle Regioni Italiane (Italian Observatory on Healthcare), 2002. He manages several undergraduate and postgraduate teaching activities. Editor of European Journal of Public Health, of Oxford Handbook of Public Health Practice and Founding Editor of Italian Journal of Public Health and of Epidemiology, Biostatistics and Public Health.“ Laurea Honoris Causa”at Thomas Jefferson University, Philadelphia, USA (2019). Appointed “Commendatore” of the Italian Republic by Decree of the President of the Republic 02 June 2017.
Dr Omolola Salako
Lecturer and Cancer Researcher, College of Medicine, University of Lagos, CEO of Oncopadi Technologies
Dr Omolola Salako is Clinical Radiation Oncologist, entrepreneur and technologist. Omolola's experience in oncology spans community, clinical, digital health solutions and research. She is the founder of several vibrant startups-Sebeccly Cancer Care, Pearl Oncology Clinics and Oncopadi Cancer App. She is committed to closing the cancer care gap and increasing access to value-driven cancer care in Sub-Saharan Africa. Omolola is the 2021 Grand Prize Winner of the C3 Astellas Oncology and she is listed as one of the "2021 Brightest Minds in Cancer Research" by the Conquer Cancer Foundation, America Society of Clinical Oncology. Omolola is a board member and advisor in several healthcare organizations and she provides strategies on oncology services, market access and healthcare innovation.
Christobel Saunders
Research and Evidence WG co-Chair and Board member, All.Can International and Professor of Surgical Oncology, University of Western Australia
Professor Saunders AO, is internationally recognised as one of Australia’s most prominent research-orientated cancer surgeons. She has substantially contributed to breast cancer research including clinical trials of new treatments, psychosocial, translational and health services research and surgical oncology cancer research. Christobel has been acknowledged through numerous awards the most recent being the AO (Order of Australia) (2018). She has performed research for >30 years and sits on the boards of a number of cancer organisations. Christobel is involved in strategic planning and management of cancer services in WA as author of the WA Health Cancer Services Framework, she is the Inaugural Chair of the state Health Service Provider, PathWest Laboratory Medicine.
Virpi Sulosaari
Principal lecturer in the Professional Master School of Health and Well-being in Turku University of Applied Sciences, Finland, Post-doctoral researcher in University of Turku, Finland
Virpi Sulosaari has a nursing background spesialised on hematology nursing. She worked many years in hematology and oncology units in university hospitals. Sulosaari did her master and doctoral degree in nursing science. Currently, she is a principal lecturer in the Professional Master School of Health and Well-being in Turku University of Applied Sciences, Finland. She is also post-doctoral researcher in University of Turku, Finland. Her expertise fields are related to cancer nursing, palliative care and under- and postgraduate nursing education. She is the current President Elect of the European Oncology Nursing Society (EONS). Recently she was principal investigator in research project that focused on interprofessional collaboration and work-related empowerment of health care professionals working in cancer care setting.